Phaseline

Companies › Telix Pharmaceuticals (Innovations)

Telix Pharmaceuticals (Innovations): clinical trials, targets and expected readouts

8 active drug programs in 11 registered trials: 5 Phase 3, 5 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
177Lu-TLX250–Phase 3ccRCC; Solid Tumor, AdultDec 2026
68Ga-PSMA-11
PSMA-targeting radioconjugate (Gallium-68 labeled PSMA ligand peptide conjugated via HBED-
FOLH1Phase 3PCAJan 2027
TLX101-Tx
Targeted radiopharmaceutical delivering radiation to glioblastoma cells
–Phase 3Neoplastic DiseaseJul 2027
177Lu-TLX591
Lutetium-177 labeled anti-PSMA antibody-drug conjugate
FOLH1Phase 3Metastatic Castration-resistant Prostate CancerDec 2027
Girentuximab (TLX250)
Carbonic anhydrase IX other
CA9Phase 3Clear Cell Renal Cell Carcinoma–
153Sm-DOTMP (TLX090-Tx)
Samarium-153 bound to diethylenetriaminepentaacetic acid (DOTMP); radiopharmaceutical that
–Phase 1Bone PainApr 2027
131I-TLX-101 (131I-IPA)
Radioiodine (131I)-labeled immunoconjugate targeting amino acid transporter; used with 18F
–Phase 1Neoplastic DiseaseJun 2027
89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)
anti-PDGFRA antibody labeled with zirconium-89 for diagnostic imaging
PDGFRAPhase 1Soft Tissue SarcomaOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06750419Girentuximab (TLX250)Phase 3Clear Cell Renal Cell CarcinomaOncologyJun 2026
NCT05868174177Lu-TLX250Phase 1Solid Tumor, AdultOncologyDec 2026
NCT05868174177Lu-TLX250Phase 1Solid Tumor, AdultOncologyDec 2026
NCT0705221468Ga-PSMA-11Phase 3PCAOncologyJan 2027
NCT07197645153Sm-DOTMP (TLX090-Tx)Phase 1Bone PainOncologyApr 2027
NCT05450744131I-TLX-101 (131I-IPA)Phase 1Neoplastic DiseaseOncologyJun 2027
NCT07100730TLX101-TxPhase 3Neoplastic DiseaseOncologyJul 2027
NCT07197580177Lu-TLX250Phase 3ccRCCOncologyAug 2027
NCT0653759689Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)Phase 1Soft Tissue SarcomaOncologyOct 2027
NCT06520345177Lu-TLX591Phase 3Metastatic Castration-resistant Prostate CancerOncologyDec 2027
NCT06447103Girentuximab (TLX250)Phase 2Clear Cell Renal Cell CarcinomaOncologyDec 2029

From the company's SEC filings

Complete response letters from FDA

Targets

FOLH1 (2) CA9 (1) PDGFRA (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) AstraZeneca PeptiDream Deciphera Pharmaceuticals Clarity Pharmaceuticals Convergent Therapeutics Fusion Pharmaceuticals Five Eleven Pharma T.O.A.D. Oncology

Companies built like this

CSPC Megalith Biopharmaceutical BeiGene RemeGen Clarity Pharmaceuticals Hansoh BioMedical R&D Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.